Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Depreciation & Amortization (CF) (2024 - 2025)

Historic Depreciation & Amortization (CF) for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $425000.0.

  • Prelude Therapeutics' Depreciation & Amortization (CF) rose 493.83% to $425000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2024, which is 5158.25% up from last year.
  • Per Prelude Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $425000.0 for Q3 2025, which was up 493.83% from $433000.0 recorded in Q2 2025.
  • Prelude Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $489000.0 during Q4 2024, with a 5-year trough of $405000.0 in Q3 2024.